Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shEZH2 is a short hairpin RNA (shRNA) construct designed to silence the expression of the Enhancer of Zeste Homolog 2 (EZH2) gene through RNA interference (RNAi). EZH2 is the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) and functions as a histone methyltransferase that methylates lysine 27 of histone H3 (H3K27), leading to transcriptional repression. In oncology research, particularly in glioblastoma multiforme (GBM), EZH2 is identified as a key regulator of glioblastoma stem cell (GSC) maintenance and tumor progression. shEZH2 is utilized as a targeted tool to downregulate EZH2 expression, thereby inhibiting downstream signaling pathways such as STAT3 activation. Preclinical studies, including those conducted at the Cleveland Clinic, have demonstrated that shEZH2-mediated knockdown can impair GSC self-renewal and, when combined with other inhibitors, extend survival in animal models of intracranial tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shEZH2.